BackgroundReal world cohorts (RWC) have demonstrated excellent efficacy of LDV/SOF for 8 weeks in HCV monoinfected patients. Real world effectiveness data of LDV/SOF for 8 weeks in HIV/HCV coinfection is emerging from several multiple single-center and multicenter prospective and retrospective cohorts. The aim of this study was to describe the effectiveness of the single tablet regimen of LDV/SOF for 8 weeks in HCV genotype (GT) 1 patients with HIV/HCV coinfection in RWC.MethodsIn this descriptive analysis, data from two prospective studies, one investigator sponsored and 1 registrational trial, one prospective RWC, three retrospective RWC of LDV/SOF for 8 weeks in HIV/HCV co-infected patients were compared. RWC were selected based on willingness to participate and had at least 15 HIV/HCV co-infected patients. The prospective trials include data from Ain et al (investigator sponsored) and Isakov et al (registrational trial). The RWC include the Deutsches Hepatitis C-Register, Madrid Coinfection Registry (Madrid-CoRe),Veterans Affairs HCV Registry, and Slim et al, representing diverse patient populations from Europe and US. Baseline characteristics and efficacy were analyzed.ResultsThe majority of the 294 patients included in this descriptive analysis were GT 1, treatment naïve (TN), noncirrhotic (NC), and had a HCV viral load < 6 million. The prospective cohorts enrolled 79 patients with the following baseline characteristics: mean age (43 years), male (66%), white (89%), and GT 1a (41%). The RWC studies assessed enrolled 215 patients with the following overall baseline characteristics: mean age (54 years) male (84%), white (82%), and GT 1a (75%) in those that reported demographics. The overall SVR12 from six diverse real world and post-marketing cohorts was 94% (277/294). The individual study results are presented in Table 1.ConclusionThis analysis of diverse cohorts from the EU and US yielded high SVR rates similar to SVR rates seen in multiple RW monoinfected cohorts and supports the use of 8 weeks of LDV/SOF in TN, NC GT 1 HIV/HCV coinfected patients with a baseline HCV viral load < 6 million.Disclosures P. Ruane, Gilead: Investigator, Scientific Advisor and Shareholder, Consulting fee and Research support; Merck: Speaker’s Bureau, Speaker honorarium; Boehringer: Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; Janssen: Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; Abbott: Investigator, Scientific Advisor and Speaker’s Bureau, Research support and Speaker honorarium; Idenix: Investigator, Research support; ViiV: Scientific Advisor and Speaker’s Bureau, Consulting fee and Speaker honorarium; BMS: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; P. Buggisch, Janssen: Scientific Advisor, Consulting fee; Abbvie: Scientific Advisor, Consulting fee; BMS: Scientific Advisor, Consulting fee; Falk: Speaker’s Bureau, Speaker honorarium; MSD: Speaker’s Bureau, Speaker honorarium; Gilead: Speaker’s Bureau, Speaker honorarium; Merz: Speaker’s Bureau, Speaker honorarium; V. Isakov, BMS: Speaker’s Bureau, Speaker honorarium; Abbvie: Scientific Advisor and Speaker’s Bureau, Consulting fee and Speaker honorarium; Gilead: Scientific Advisor and Speaker’s Bureau, Consulting fee and Speaker honorarium; Merck: Scientific Advisor and Speaker’s Bureau, Consulting fee and Speaker honorarium; Janssen: Scientific Advisor and Speaker’s Bureau, Consulting fee and Speaker honorarium; R-Pharm: Scientific Advisor and Speaker’s Bureau, Consulting fee and Speaker honorarium; J. Gonzalez-Garcia, Gilead: Board Member and Speaker’s Bureau, Speaker honorarium; MSD: Speaker’s Bureau, Speaker honorarium; Abbvie: Board Member and Speaker’s Bureau, Speaker honorarium; Janssen: Board Member and Speaker’s Bureau, Speaker honorarium; Ciliag: Speaker’s Bureau, Speaker honorarium; BMS: Board Member and Speaker’s Bureau, Speaker honorarium; S. Naik, Gilead Sciences: Employee, Salary; S. Mehta, Gilead Sciences: Employee, Salary; J. Lee, Gilead Sciences: Employee, Salary; J. Llewellyn, Gilead Sciences: Employee, Salary; M. Mertens, Gilead Sciences: Employee, Salary; M. Natha, Gilead Sciences: Employee, Salary; A. Osinusi, Gilead Sciences: Employee, Salary; J. Slim, Gilead: CME/CE, Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; Abbvie: CME/CE, Consultant and Investigator, Consulting fee, Research support and Speaker honorarium; Merck: CME/CE, Consultant and Investigator, Consulting fee, Research support and Speaker honorarium; ViiV: CME/CE, Consultant and Investigator, Consulting fee, Research support and Speaker honorarium; Janssen: CME/CE and Consultant, Consulting fee and Speaker honorarium; BMS: CME/CE, Speaker honorarium; K. Zhdanov, MSD: Speaker’s Bureau, Speaker honorarium; Novartis: Speaker’s Bureau, Speaker honorarium; Roche: Speaker’s Bureau, Speaker honorarium; Biocad: Speaker’s Bureau, Speaker honorarium; BMS: Consultant, Consulting fee; Abbvie: Investigator, Research support; Gilead: Investigator, Research support; R-Pharm: Investigator, Research support; Janssen: Scientific Advisor, Consulting fee; S. Zeuzem, Abbvie: Consultant, Consulting fee; Gilead: Consultant, Consulting fee; Merck: Consultant, Consulting fee; BMS: Consultant, Consulting fee; Janssen: Consultant, Consulting fee